A Phase II Study of 131I-rituximab for Patients With Relapsed or Refractory Marginal Zone Lymphoma
{{output}}
Background: Radioimmunotherapy (RIT) is a rare treatment option for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). We investigated the safety and efficacy of 131I-rituximab in patients with relapsed or refractory mar... ...